Matthias Hübenthal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matthias Hübenthal has a total of 395 co-authors. Here are the top co-authors by number of shared publications:
Andre Franke
Institute of Clinical Molecular Biology Kiel University Kiel Germany
14 shared publications- Stephan Weidinger
Center for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
9 shared publications Wolfgang Lieb
Institute of Epidemiology and Biobank popgen, Christian-Albrechts-University of Kiel, Kiel, Germany
8 shared publications- Mauro D' Amato
Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA, Derio, Spain
7 shared publications David Ellinghaus
Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany
6 shared publicationsStefan Schreiber
Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany
6 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (10) , 1441-1452
Psychoedukativer schematherapeutischer Ansatz bei Psoriasis und atopischer Dermatitis: Eine randomisierte kontrollierte Pilot‐Crossover‐Studie
Zusammenfassung: Hintergrund und Ziele: Atopische Dermatitis und Psoriasis sind chronisch‐entzündliche Hauterkrankungen, die häufig mit psychischem Stress einhergehen. Integrative Versorgungsmodelle fehlen weitestgehend. Diese randomisierte Pilotstudie hatte zum Ziel, zu der dermatologischen Behandlung eine begleitende schematherapeutisch ausgerichtete psychoedukative Kurzzeitintervention für dermatologische Patienten zu entwickeln und zu testen. Patienten und Methodik: Patienten aus einem ambulanten Entzündungszentrum mit einem PHQ‐2 (Patient Health Questionnaire‐2) Score ≥ 3 wurden randomisiert und einer Interventions‐ oder Kontrollgruppe zugewiesen. Die Interventionsgruppe erhielt drei standardisierte Sitzungen mit den Schwerpunkten maladaptive Schemata, Bewältigungsstrategien, Psychoedukation und emotionsfokussierte Techniken (zum Beispiel Stuhldialoge, Imagination). Ergebnisse: 19 Betroffene erhielten die Intervention, 13 gehörten zur Kontrollgruppe. Nach der Intervention wurden signifikante Verbesserungen der dermatologischen Lebensqualität (DLQI), des subjektiven Wohlbefindens (WHO‐5) und der depressiven Symptome (PHQ‐9, BDI‐II) beobachtet. Sie waren weitgehend unabhängig vom Schweregrad der Erkrankung (PASI, EASI). Qualitative Rückmeldungen hoben die Benutzerfreundlichkeit, das Erlernen spezifischer Techniken und eine vertrauensvolle therapeutische Beziehung hervor. Schlussfolgerungen: Eine kurze psychologische Intervention reduziert die psychische Belastung bei dermatologischen ambulanten Patienten signifikant. Weitere Studien sollten die langfristigen Auswirkungen und eine breitere Umsetzung untersuchen.
- 5 October 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (10) , 1441-1452
Open AccessPsychoedukativer schematherapeutischer Ansatz bei Psoriasis und atopischer Dermatitis: Eine randomisierte kontrollierte Pilot‐Crossover‐Studie
Zusammenfassung: Hintergrund und Ziele: Atopische Dermatitis und Psoriasis sind chronisch‐entzündliche Hauterkrankungen, die häufig mit psychischem Stress einhergehen. Integrative Versorgungsmodelle fehlen weitestgehend. Diese randomisierte Pilotstudie hatte zum Ziel, zu der dermatologischen Behandlung eine begleitende schematherapeutisch ausgerichtete psychoedukative Kurzzeitintervention für dermatologische Patienten zu entwickeln und zu testen. Patienten und Methodik: Patienten aus einem ambulanten Entzündungszentrum mit einem PHQ‐2 (Patient Health Questionnaire‐2) Score ≥ 3 wurden randomisiert und einer Interventions‐ oder Kontrollgruppe zugewiesen. Die Interventionsgruppe erhielt drei standardisierte Sitzungen mit den Schwerpunkten maladaptive Schemata, Bewältigungsstrategien, Psychoedukation und emotionsfokussierte Techniken (zum Beispiel Stuhldialoge, Imagination). Ergebnisse: 19 Betroffene erhielten die Intervention, 13 gehörten zur Kontrollgruppe. Nach der Intervention wurden signifikante Verbesserungen der dermatologischen Lebensqualität (DLQI), des subjektiven Wohlbefindens (WHO‐5) und der depressiven Symptome (PHQ‐9, BDI‐II) beobachtet. Sie waren weitgehend unabhängig vom Schweregrad der Erkrankung (PASI, EASI). Qualitative Rückmeldungen hoben die Benutzerfreundlichkeit, das Erlernen spezifischer Techniken und eine vertrauensvolle therapeutische Beziehung hervor. Schlussfolgerungen: Eine kurze psychologische Intervention reduziert die psychische Belastung bei dermatologischen ambulanten Patienten signifikant. Weitere Studien sollten die langfristigen Auswirkungen und eine breitere Umsetzung untersuchen.
- Open Access
- 19 March 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (10)
Psychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial
Summary: Background and objectives: Atopic dermatitis and psoriasis are chronic inflammatory skin diseases often linked to psychological stress. Integrative care models are lacking. This randomized pilot study aimed to develop and test a psychoeducational intervention for dermatology patients. Patients and methods: Patients with a PHQ‐2 score ≥ 3 at an outpatient inflammation center were randomized into an intervention or control group. The intervention group received three standardized educational sessions focusing on maladaptive schemas, coping strategies, psychoeducation, and emotion‐focused techniques (e.g. chair‐dialogues, imaginary rescripting). Results: 19 patients received the intervention; 13 were in the control group. Post‐intervention, significant improvements were observed in dermatological quality of life (DLQI), subjective well‐being (WHO‐5), and depressive symptoms (PHQ‐9, BDI‐II). Psychological benefits were largely independent of disease severity (PASI, EASI). Qualitative feedback highlighted usability, learning specific techniques, and a trusting therapeutic relationship. Conclusions: A brief psychoeducational intervention significantly reduced psychological stress in dermatology outpatients. Further studies are needed to evaluate long‐term effects and broader implementation.
- 19 March 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (10)
Open AccessPsychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial
Summary: Background and objectives: Atopic dermatitis and psoriasis are chronic inflammatory skin diseases often linked to psychological stress. Integrative care models are lacking. This randomized pilot study aimed to develop and test a psychoeducational intervention for dermatology patients. Patients and methods: Patients with a PHQ‐2 score ≥ 3 at an outpatient inflammation center were randomized into an intervention or control group. The intervention group received three standardized educational sessions focusing on maladaptive schemas, coping strategies, psychoeducation, and emotion‐focused techniques (e.g. chair‐dialogues, imaginary rescripting). Results: 19 patients received the intervention; 13 were in the control group. Post‐intervention, significant improvements were observed in dermatological quality of life (DLQI), subjective well‐being (WHO‐5), and depressive symptoms (PHQ‐9, BDI‐II). Psychological benefits were largely independent of disease severity (PASI, EASI). Qualitative feedback highlighted usability, learning specific techniques, and a trusting therapeutic relationship. Conclusions: A brief psychoeducational intervention significantly reduced psychological stress in dermatology outpatients. Further studies are needed to evaluate long‐term effects and broader implementation.
- Open Access
- 1 March 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 14 (1)
Robust prediction of response to growth hormone therapy by five PBMC-based transcripts
- 1 March 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 14 (1)
Open AccessRobust prediction of response to growth hormone therapy by five PBMC-based transcripts
- Open Access
- 2 December 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (3) , 597-599
The Inflammatory Skin Disease map: an interactive computational resource focused on molecular mechanisms in psoriasis and atopic dermatitis
In this research letter, we introduce the Inflammatory Skin Diseases (ISD) map, a visual and computational representation of a molecular interaction network of molecular mechanisms of atopic dermatitis (AD) and psoriasis (PsO) (https://disease-maps.io/isd/). This knowledge repository can be used as a graphical review, to visualize complex omics data, or as a simulation testbed for research hypotheses. The purpose of the ISD map is to represent key molecular mechanisms of AD and PsO, facilitating information search and data interpretation, and supporting computational analyses.
- 2 December 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (3) , 597-599
Open AccessThe Inflammatory Skin Disease map: an interactive computational resource focused on molecular mechanisms in psoriasis and atopic dermatitis
In this research letter, we introduce the Inflammatory Skin Diseases (ISD) map, a visual and computational representation of a molecular interaction network of molecular mechanisms of atopic dermatitis (AD) and psoriasis (PsO) (https://disease-maps.io/isd/). This knowledge repository can be used as a graphical review, to visualize complex omics data, or as a simulation testbed for research hypotheses. The purpose of the ISD map is to represent key molecular mechanisms of AD and PsO, facilitating information search and data interpretation, and supporting computational analyses.
- Open Access
- 27 December 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (7) , 1643-1652.e13
Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response
- 27 December 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (7) , 1643-1652.e13
Open AccessTralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response
- Open Access
- 30 August 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (1) , 100309
Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study
- 30 August 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (1) , 100309
Open AccessType 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study
- Open Access
- 31 May 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (4) , 637-639
Mapping SCORing of Atopic Dermatitis (SCORAD) and objective SCORAD to the Eczema Area and Severity Index to facilitate large-scale meta-analyses of molecular data
We used data from 1501 patients to build mathematical models for mapping between common measures of atopic dermatitis severity, including SCORing of Atopic Dermatitis (SCORAD), objective SCORAD (oSORAD) and the Eczema Area and Severity Index (EASI). These models can be used to facilitate progress in harmonizing patient data across studies, enabling important comparative analyses at scale.
- 31 May 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (4) , 637-639
Open AccessMapping SCORing of Atopic Dermatitis (SCORAD) and objective SCORAD to the Eczema Area and Severity Index to facilitate large-scale meta-analyses of molecular data
We used data from 1501 patients to build mathematical models for mapping between common measures of atopic dermatitis severity, including SCORing of Atopic Dermatitis (SCORAD), objective SCORAD (oSORAD) and the Eczema Area and Severity Index (EASI). These models can be used to facilitate progress in harmonizing patient data across studies, enabling important comparative analyses at scale.
- Open Access
- 18 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 204-216
Phenotype–Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism
Although great progress has been made in the fine‐tuning of diplotypes, there is still a need to further improve the predictability of individual phenotypes of pharmacogenetically relevant enzymes. The aim of this study was to analyze the additional contribution of sex and variants identified by exome chip analysis to the metabolic ratio of five probe drugs. A cocktail study applying dextromethorphan, losartan, omeprazole, midazolam, and caffeine was conducted on 200 healthy volunteers. CYP2D6, 2C9, 2C19, 3A4/5, and 1A2 genotypes were analyzed and correlated with metabolic ratios. In addition, an exome chip analysis was performed. These SNPs correlating with metabolic ratios were confirmed by individual genotyping. The contribution of various factors to metabolic ratios was assessed by multiple regression analysis. Genotypically predicted phenotypes defined by CPIC discriminated very well the log metabolic ratios with the exception of caffeine. There were minor sex differences in the activity of CYP2C9, 2C19, 1A2, and CYP3A4/5. For dextromethorphan (CYP2D6), IP6K2 (rs61740999) and TCF20 (rs5758651) affected metabolic ratios, but only IP6K2 remained significant after multiple regression analysis. For losartan (CYP2C9), FBXW12 (rs17080138), ZNF703 (rs79707182), and SLC17A4 (rs11754288) together with CYP diplotypes, and sex explained 50% of interindividual variability. For omeprazole (CYP2C19), no significant influence of CYP2C:TG haplotypes was observed, but CYP2C19 rs12777823 improved the predictability. The comprehensive genetic analysis and inclusion of sex in a multiple regression model significantly improved the explanation of variability of metabolic ratios, resulting in further improvement of algorithms for the prediction of individual phenotypes of drug‐metabolizing enzymes.
- 18 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 204-216
Open AccessPhenotype–Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism
Although great progress has been made in the fine‐tuning of diplotypes, there is still a need to further improve the predictability of individual phenotypes of pharmacogenetically relevant enzymes. The aim of this study was to analyze the additional contribution of sex and variants identified by exome chip analysis to the metabolic ratio of five probe drugs. A cocktail study applying dextromethorphan, losartan, omeprazole, midazolam, and caffeine was conducted on 200 healthy volunteers. CYP2D6, 2C9, 2C19, 3A4/5, and 1A2 genotypes were analyzed and correlated with metabolic ratios. In addition, an exome chip analysis was performed. These SNPs correlating with metabolic ratios were confirmed by individual genotyping. The contribution of various factors to metabolic ratios was assessed by multiple regression analysis. Genotypically predicted phenotypes defined by CPIC discriminated very well the log metabolic ratios with the exception of caffeine. There were minor sex differences in the activity of CYP2C9, 2C19, 1A2, and CYP3A4/5. For dextromethorphan (CYP2D6), IP6K2 (rs61740999) and TCF20 (rs5758651) affected metabolic ratios, but only IP6K2 remained significant after multiple regression analysis. For losartan (CYP2C9), FBXW12 (rs17080138), ZNF703 (rs79707182), and SLC17A4 (rs11754288) together with CYP diplotypes, and sex explained 50% of interindividual variability. For omeprazole (CYP2C19), no significant influence of CYP2C:TG haplotypes was observed, but CYP2C19 rs12777823 improved the predictability. The comprehensive genetic analysis and inclusion of sex in a multiple regression model significantly improved the explanation of variability of metabolic ratios, resulting in further improvement of algorithms for the prediction of individual phenotypes of drug‐metabolizing enzymes.
- Open Access
A novel unconventional T cell population enriched in Crohn’s disease
Objective: One of the current hypotheses to explain the proinflammatory immune response in IBD is a dysregulated T cell reaction to yet unknown intestinal antigens. As such, it may be possible to identify disease-associated T cell clonotypes by analysing the peripheral and intestinal T-cell receptor (TCR) repertoire of patients with IBD and controls. Design: We performed bulk TCR repertoire profiling of both the TCR alpha and beta chains using high-throughput sequencing in peripheral blood samples of a total of 244 patients with IBD and healthy controls as well as from matched blood and intestinal tissue of 59 patients with IBD and disease controls. We further characterised specific T cell clonotypes via single-cell RNAseq. Results: We identified a group of clonotypes, characterised by semi-invariant TCR alpha chains, to be significantly enriched in the blood of patients with Crohn’s disease (CD) and particularly expanded in the CD8 + T cell population. Single-cell RNAseq data showed an innate-like phenotype of these cells, with a comparable gene expression to unconventional T cells such as mucosal associated invariant T and natural killer T (NKT) cells, but with distinct TCRs. Conclusions: We identified and characterised a subpopulation of unconventional Crohn-associated invariant T (CAIT) cells. Multiple evidence suggests these cells to be part of the NKT type II population. The potential implications of this population for CD or a subset thereof remain to be elucidated, and the immunophenotype and antigen reactivity of CAIT cells need further investigations in future studies.
Open AccessA novel unconventional T cell population enriched in Crohn’s disease
Objective: One of the current hypotheses to explain the proinflammatory immune response in IBD is a dysregulated T cell reaction to yet unknown intestinal antigens. As such, it may be possible to identify disease-associated T cell clonotypes by analysing the peripheral and intestinal T-cell receptor (TCR) repertoire of patients with IBD and controls. Design: We performed bulk TCR repertoire profiling of both the TCR alpha and beta chains using high-throughput sequencing in peripheral blood samples of a total of 244 patients with IBD and healthy controls as well as from matched blood and intestinal tissue of 59 patients with IBD and disease controls. We further characterised specific T cell clonotypes via single-cell RNAseq. Results: We identified a group of clonotypes, characterised by semi-invariant TCR alpha chains, to be significantly enriched in the blood of patients with Crohn’s disease (CD) and particularly expanded in the CD8 + T cell population. Single-cell RNAseq data showed an innate-like phenotype of these cells, with a comparable gene expression to unconventional T cells such as mucosal associated invariant T and natural killer T (NKT) cells, but with distinct TCRs. Conclusions: We identified and characterised a subpopulation of unconventional Crohn-associated invariant T (CAIT) cells. Multiple evidence suggests these cells to be part of the NKT type II population. The potential implications of this population for CD or a subset thereof remain to be elucidated, and the immunophenotype and antigen reactivity of CAIT cells need further investigations in future studies.
- Top Cited PapersOpen Access
- 5 November 2021
- Published by Springer Nature in Nature Genetics
- Vol. 53 (11) , 1543-1552
Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders
Irritable bowel syndrome (IBS) results from disordered brain–gut interactions. Identifying susceptibility genes could highlight the underlying pathophysiological mechanisms. We designed a digestive health questionnaire for UK Biobank and combined identified cases with IBS with independent cohorts. We conducted a genome-wide association study with 53,400 cases and 433,201 controls and replicated significant associations in a 23andMe panel (205,252 cases and 1,384,055 controls). Our study identified and confirmed six genetic susceptibility loci for IBS. Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6. The first four are associated with mood and anxiety disorders, expressed in the nervous system, or both. Mirroring this, we also found strong genome-wide correlation between the risk of IBS and anxiety, neuroticism and depression (rg > 0.5). Additional analyses suggested this arises due to shared pathogenic pathways rather than, for example, anxiety causing abdominal symptoms. Implicated mechanisms require further exploration to help understand the altered brain–gut interactions underlying IBS.
- 5 November 2021
- Published by Springer Nature in Nature Genetics
- Vol. 53 (11) , 1543-1552
Top Cited PapersOpen AccessGenome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders
Irritable bowel syndrome (IBS) results from disordered brain–gut interactions. Identifying susceptibility genes could highlight the underlying pathophysiological mechanisms. We designed a digestive health questionnaire for UK Biobank and combined identified cases with IBS with independent cohorts. We conducted a genome-wide association study with 53,400 cases and 433,201 controls and replicated significant associations in a 23andMe panel (205,252 cases and 1,384,055 controls). Our study identified and confirmed six genetic susceptibility loci for IBS. Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6. The first four are associated with mood and anxiety disorders, expressed in the nervous system, or both. Mirroring this, we also found strong genome-wide correlation between the risk of IBS and anxiety, neuroticism and depression (rg > 0.5). Additional analyses suggested this arises due to shared pathogenic pathways rather than, for example, anxiety causing abdominal symptoms. Implicated mechanisms require further exploration to help understand the altered brain–gut interactions underlying IBS.